Table 5. Clinical characteristics and endoscopic findings according to combination antiretroviral therapy duration in the patients with good adherence.

				≤6 M (N = 58)	>6 M ~ ≤5 Y (N = 60)	>5 Y ~ ≤10 Y (N = 55)	>10 Y (N = 27)	P-value
Age, years, median (IQR)				47.5 (39.8–55.5)	53 (43.3–60)	55 (50–62)	59 (54–67)	<0.001
Male sex, No. (%)				49 (84.5)	53 (88.3)	48 (87.3)	23 (85.2)	0.931
CD4 cell count/mm3, median (IQR)				107.5 (36.5–296.0)	457 (262.5–610.8)	612 (464.5–793.3)	595 (530–852)	<0.001
CD4 cell count <200/ mm3, No. (%)				33 (56.9)	7 (11.7)	2 (3.6)	0 (2.9)	<0.001
HIV RNA virus, log/mL, median (IQR)				5 (2.8–5.5)	0 (0–0)	0 (0–0)	0 (0–0)	<0.001
The median observation period, years (IQR)				0.1 (0–0.3)	3.0 (1.5–4.2)	7.6 (5.2–18.8)	12.0 (11.2–13.8)	<0.001
The median cART period, years (IQR)				0 (0–0.1)	2.5 (1.2–3.6)	6.7 (5.1–9.7)	11.5 (10.9–13.0)	<0.001
Endoscopic finding, No. (%)
	Opportunistic infection			16 (27.6)	5 (8.3)	0 (0.0)	2 (7.4)	<0.001
	Esophagus
		Reflux esophagitis		15 (25.9)	16 (26.7)	20 (36.4)	4 (14.8)	0.217
		Esophageal candidiasis		14 (24.1)	5 (8.3)	0 (0.0)	2 (7.4)	<0.001
		Esophageal ulcer		8 (13.8)	3 (5.0)	1 (1.8)	0 (0.0)	0.035
			CMV esophagitis	4 (6.9)	0 (0.0)	0 (0.0)	0 (0.0)	0.020
	Stomach
		Atrophic gastritis		26 (44.8)	32 (53.3)	39 (70.9)	22 (81.5)	0.002
		Erosive gastritis		10 (17.2)	13 (21.7)	20 (36.4)	10 (37.0)	0.056
		Erythematous gastritis		22 (37.9)	19 (31.7)	13 (23.6)	4 (14.8)	0.119
		Intestinal metaplasia		11 (19.0)	15 (25.0)	19 (34.5)	8 (29.6)	0.293
		Gastric ulcer		8 (13.8)	4 (6.7)	7 (12.7)	3 (11.1)	0.619
		Gastric cancer		0 (0.0)	1 (1.4)	1 (1.7)	1 (2.9)	0.486
		Kaposi sarcoma		1 (1.7)	0 (0.0)	0 (0.0)	0 (0.0)	1.000
	Duodenum
		Duodenal ulcer		1 (1.7)	1 (1.7)	1 (1.8)	2 (7.4)	0.467
		Duodenitis		7 (12.1)	3 (5.0)	3 (5.0)	0 (0.0)	0.202

M, month; Y, year; IQR, interquartile range; HIV, human immunodeficiency virus; cART, combination antiretroviral therapy; CMV, cytomegalovirus.